Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mingfule (rhTNK-tPA) versus standard medication for acute large-vessel ischemic stroke treated 4.5-24 hours after onset
ChiCTR2100053567Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke and Ischaemic cerebral disease (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of subjects with modified Rankin Scale score 0-1 at 90 days. Started Mar 2022; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic strokeIschaemic cerebral disease
Beyond the preview
Go deeper on ChiCTR2100053567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053567.